The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 501–600 of 1,001
Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib
Li, Y., Wang, J., Pan, C., Meng, F., Chu, X.-Q., Ding, Y., Qu, W.-Z., Li, H., Yang, C., Zhang, Q., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.068 · Cited by 43
Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting
Förster, M., Gehringer, M., & Laufer, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.079 · Cited by 43
Comment on The Ecstasy and Agony of Assay Interference Compounds
Kenny, P. W. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00313 · Cited by 43
The Nitro Group as a Masked Electrophile in Covalent Enzyme Inhibition
Ray, S., Kreitler, D. F., Gulick, A. M., & Murkin, A. S. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00225 · Cited by 42
Covalent binders in drug discovery
Vasudevan, A., Argiriadi, M. A., Baranczak, A., Friedman, M., Gavrilyuk, J. I., Hobson, A. D., Hulce, J. J., Osman, S., & Wilson, N. S. (2019) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.12.002 · Cited by 46
A Fast Ab Initio Predictor Tool for Covalent Reactivity Estimation of Acrylamides
Palazzesi, F., Grundl, M. A., Pautsch, A., Weber, A., & Tautermann, C. S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00316 · Cited by 42
An updated patent review of anticancer Hsp90 inhibitors (2013-present)
Li, L., Chen, N., You, Q., & Xu, X. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1829595 · Cited by 44
Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma
Miranda, R. R., Fu, Y., Chen, X., Perino, J., Cao, P., Carpten, J. D., Chen, Y., & Zhang, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00044 · Cited by 46
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules
Goebel, G. L., Qiu, X., & Wu, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.006 · Cited by 44
Malona, J., Chuaqui, C. E., Seletsky, B. M., Beebe, L., Cantin, S. M., van Kalken, D., Fahnoe, K. C., WANG, Z., Browning, B., Szabo, H., et al. (2022) · Translational research · doi:10.1016/j.trsl.2022.06.005 · Cited by 51
“To create an MK2 inhibitor that addresses these hurdles, we turned to engineering a targeted covalent inhibitor (TCI), a strategy that has worked for addressing potency and other challenges for kinase-targeted therapies.(26,27)”
BackgroundDrug–Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization
Gan, J., Zhang, H., & Humphreys, W. G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00274 · Cited by 46
Wang, J., Lam, D., Yang, J., & Hu, L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02952-5 · Cited by 43
“In the structure-based design of osimertinib, starting with reversible inhibitors with known affinity to EGFR double mutant led to the identification of favorable hydrogen bonding interactions with the hinge residue M793, and enabled the incorporation of less reactive electrophiles [45, 49].”
BackgroundYu, W., Zhao, Y., Ye, H., Wu, N., Liao, Y., Chen, N., Li, Z., Wan, N., Hao, H., Yan, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00954 · Cited by 46
Divergent synthesis and identification of the cellular targets of deoxyelephantopins
Lagoutte, R., Serba, C., Abegg, D., Hoch, D. G., Adibekian, A., & Winssinger, N. (2016) · Nature Communications · doi:10.1038/ncomms12470 · Cited by 41
Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign
Baillie, T. A. (2016) · Angewandte Chemie · doi:10.1002/ange.201601091 · Cited by 44
Self-citationWang, Y., Dai, Y., Wu, X., Li, F., Liu, B., Li, C., Liu, Q., Zhou, Y., Bao, W., Zhu, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00510 · Cited by 43
Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide
Yamane, D., Onitsuka, S., Re, S., Isogai, H., Hamada, R., Hiramoto, T., Kawanishi, E., Mizuguchi, K., Shindo, N., & Ojida, A. (2022) · Chemical Science · doi:10.1039/d1sc06596c · Cited by 44
Profiling the proteome-wide selectivity of diverse electrophilesPreprint
Zanon, P. R. A., Yu, F., Musacchio, P. Z., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-w7rss-v2 · Cited by 55
Covalent Inhibitors: To Infinity and Beyond
Raouf, Y. S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01308 · Cited by 50
Meng, J., Liu, X.-Y., Ma, S., Zhang, H., Yu, S.-D., Zhang, Y.-F., Chen, M.-X., Zhu, X.-Y., Liu, Y., Yi, L., et al. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0176-6 · Cited by 41
Tallon, A. M., Xu, Y., West, G. M., am Ende, C. W., & Fox, J. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04444 · Cited by 43
A Disalicylic Acid‐Furanyl Derivative Inhibits Ephrin Binding to a Subset of Eph Receptors
Noberini, R., De, S. K., Zhang, Z., Wu, B., Raveendra‐Panickar, D., Chen, V., Vazquez, J., Qin, H., Song, J., Cosford, N. D. P., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01199.x · Cited by 41
Li, X., Liu, N., Zhang, H., Knudson, S. E., Li, H., Lai, C., Simmerling, C. L., Slayden, R. A., & Tonge, P. J. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200141e · Cited by 41
Seow, V., Lim, J., Cotterell, A. J., Yau, M., Xu, W., Lohman, R., Kok, W. M., Stoermer, M. J., Sweet, M. J., Reid, R. C., et al. (2016) · Scientific Reports · doi:10.1038/srep24575 · Cited by 40
Applications of Reactive Cysteine Profiling
Backus, K. M. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_120 · Cited by 43
Bianco, G., Goodsell, D. S., & Forli, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.005 · Cited by 44
“Over the years, there has been an on-going debate on the liability of idiosyncratic toxicity [1] with covalent drugs.”
BackgroundInfluentialDocking Paradigm in Drug Design
Sulimov, V. B., Kutov, D. C., Taschilova, A. S., Ilin, I. S., Tyrtyshnikov, E. E., & Sulimov, A. V. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201207095626 · Cited by 45
Chemoproteomic profiling of kinases in live cells using electrophilic sulfonyl triazole probes
Huang, T., Hosseinibarkooie, S., Borne, A. L., Granade, M. E., Brulet, J. W., Harris, T. E., Ferris, H. A., & Hsu, K. (2021) · Chemical Science · doi:10.1039/d0sc06623k · Cited by 42
New covalent bonding ability for proteins
Cao, L., & Wang, L. (2021) · Protein Science · doi:10.1002/pro.4228 · Cited by 39
“Small molecule covalent drugs provide desirable therapeutic properties over noncovalent ones for treating challenging diseases.(38) The potential of covalent protein drugs, however, remains largely untapped due to protein's inability to bind targets covalently.”
BackgroundThe Scarlet Letter of Alkylation: A Mini Review of Selective Alkylating Agents
Oronsky, B. T., Reid, T. R., Knox, S. J., & Scicinski, J. J. (2012) · Translational Oncology · doi:10.1593/tlo.12187 · Cited by 41
Tang, G., Wang, W., Zhu, C., Huang, H., Chen, P., Wang, X., Xu, M., Sun, J., Zhang, C., Xiao, Q., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202316394 · Cited by 40
Hou, B., Ye, J., Huang, L., Cheng, W., Chen, F., Zhou, H., Pan, J., Gao, J., Lai, Y., Zhao, Y., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq3940 · Cited by 43
“The covalent inhibitors display enhanced binding affinity and potency, a prolonged action duration that surpasses the pharmacokinetics of the drug, an improved therapeutic index by reducing the dosage and frequency of administration, and the potential to suppress refractory targets ( 13 , 14 ).”
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Fouqué, A., Delalande, O., Jean, M., Castellano, R., Josselin, E., Malleter, M., Shoji, K. F., Mac, D. H., Rampanarivo, H., Collette, Y., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00991 · Cited by 43
Focus on PAINS: false friends in the quest for selective anti-protozoal lead structures from Nature?
Glaser, J., & Holzgrabe, U. (2016) · MedChemComm · doi:10.1039/c5md00481k · Cited by 41
Chang, C., Chern, J., Chen, M., Huang, K.-F., Chen, C.-H., Yang, Y., & Wu, S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja510375f · Cited by 44
Proteomics and Beyond: Cell Decision-Making Shaped by Reactive Electrophiles
Liu, X., Long, M. J. C., & Aye, Y. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.014 · Cited by 41
“It has been successfully demonstrated in combating the occurrence of drugresistant cancer mutations[57, 58].”
BackgroundPolypharmacology of andrographolide: beyond one molecule one target
Tran, Q. T. N., Tan, W. S. D., Wong, W. S. F., & Chai, C. L. L. (2020) · Natural Product Reports · doi:10.1039/d0np00049c · Cited by 40
Liu, Y., Lv, S., Peng, L., Xie, C., Gao, L., Sun, H., Lin, L., Ding, K., & Li, Z. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114636 · Cited by 42
Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors
Kirk, C. J., Muchamuel, T., Wang, J., & Fan, R. (2021) · Cells · doi:10.3390/cells11010009 · Cited by 44
“Given the risk of off-target activity for covalent inhibitors, reduced exposure time is considered a desirable physicochemical property, even for those with minimal offtarget reactivity [46,47].”
BackgroundSynthesis of Novel Tricyclic Chromenone-Based Inhibitors of IRE-1 RNase Activity
Ranatunga, S., Tang, C.-H. A., Kang, C. W., Kriss, C. L., Kloppenburg, B. J., Hu, C. A., & Valle, J. R. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5002452 · Cited by 43
Targeting protein disorder: the next hurdle in drug discovery
Lázár, T., Connor, A., DeLisle, C. F., Burger, V., & Tompa, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01220-6 · Cited by 52
“other proteins in the proteome, but it can offer increased potency and prolonged target engagement, as demonstrated by several marketed drugs 78 .”
Target-Based Molecular Modeling Strategies for Schistosomiasis Drug Discovery
Ferreira, L. L. G., Oliva, G., & Andricopulo, A. D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.21 · Cited by 43
Targeted Covalent Enzyme Inhibitors
Noe, M. C., & Gilbert, A. M. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00027-8 · Cited by 49
Laprairie, R. B., Kulkarni, A., Kulkarni, P. M., Hurst, D. P., Lynch, D. L., Reggio, P. H., Janero, D. R., Pertwee, R. G., Stevenson, L., Kelly, M. E. M., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00041 · Cited by 42
Intramembrane proteases as drug targets
Verhelst, S. H. L. (2016) · FEBS Journal · doi:10.1111/febs.13979 · Cited by 40
Yu, Y., Nie, Y., Feng, Q., Qu, J., Wang, R., Bian, L., & Xia, J. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00952 · Cited by 39
Wang, L., Zhao, J., Yao, Y., Wang, C., Zhang, J., Shu, X. H., Sun, X., Li, Y., Liu, K., Yuan, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.024 · Cited by 43
Goess, C., Harris, C. M., Murdock, S., McCarthy, R. W., Sampson, E. R., Twomey, R., Mathieu, S., Mario, R., Perham, M., Goedken, E. R., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1484269 · Cited by 38
“That is, non-covalent, off-target interactions are only likely to occur at sustained drug levels and most off-target impacts will be short lived due to the rapid clearance of ABBV-105 [40].”
BackgroundQin, L., Yuan, X. M., Cui, Y., Sun, Q., Duan, X., Zhuang, K., Chen, L., Qiu, J., & Guo, K. (2020) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202000716 · Cited by 39
Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides
Charoenpattarapreeda, J., Tan, Y. S., Iegre, J., Walsh, S. J., Fowler, E., Eapen, R. S., Wu, Y., Sore, H. F., Verma, C. S., Itzhaki, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04022f · Cited by 35
Wang, S., Faucher, F. F., Bertolini, M., Kim, H., Yu, B., Cao, L., Röltgen, K., Lovell, S., Shanker, V. R., Boyd, S. D., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c15843 · Cited by 42
Self-assembly induced solubilization of drug-like molecules in nanostructured ionic liquids
Jin, W., Yang, Q., Zhang, Z., Bao, Z., Ren, Q., Yang, Y., & Xing, H. (2015) · Chemical Communications · doi:10.1039/c5cc03463a · Cited by 41
An Allenic Pauson–Khand Approach to 6,12-Guaianolides
Grillet, F., Huang, C., & Brummond, K. M. (2011) · Organic Letters · doi:10.1021/ol2028515 · Cited by 38
Deng, H., Sun, H., & Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.07.005 · Cited by 44
Chemical biology approaches to target validation in cancer
Blagg, J., & Workman, P. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.007 · Cited by 41
Determining molecular properties with differential mobility spectrometry and machine learning
Walker, S. W. C., Anwar, A., Psutka, J. M., Crouse, J., Liu, C., Blanc, J. C. Y. L., Montgomery, J. I., Goetz, G. H., Janiszewski, J. S., Campbell, J. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07616-w · Cited by 42
Degradable pH and redox dual responsive nanoparticles for efficient covalent drug delivery
Du, J., Choi, B., Liu, Y., Feng, A., & Thang, S. H. (2019) · Polymer Chemistry · doi:10.1039/c8py01583j · Cited by 40
Ma, Y., Li, L., He, S., Shang, C., Sun, Y., Liu, N., Meek, T. D., Wang, Y., & Shang, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00387 · Cited by 39
Dražić, T., Kopf, S., Corridan, J., Leuthold, M. M., Bertoša, B., & Klein, C. D. P. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00759 · Cited by 38
Comparative reactivity analysis of small-molecule thiol surrogates
Petri, L., Ábrányi‐Balogh, P., Varga, P. R., Imre, T., & Keserű, G. M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115357 · Cited by 40
Stereodefined rhodium-catalysed 1,4-H/D delivery for modular syntheses and deuterium integration
Wang, W., Yu, Y., Cheng, B. H., Fang, H., Zhang, X., Qian, H., & Ma, S. (2021) · Nature Catalysis · doi:10.1038/s41929-021-00643-9 · Cited by 38
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105806 · Cited by 41
Identification of Ebsulfur Analogues with Broad‐Spectrum Antifungal Activity
Ngo, H. X., Shrestha, S. K., & Garneau‐Tsodikova, S. (2016) · ChemMedChem · doi:10.1002/cmdc.201600236 · Cited by 38
Li, S., Zhang, P., Xu, F., Hu, S., Liu, J.-C., Tan, Y., Tu, Z., Sun, H., Zhang, Z., He, Q., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00272 · Cited by 40
Manish, M., Mishra, S., Anand, A., & Subbarao, N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106125 · Cited by 40
Yang, J., Li, C.-L. F., Ding, L., Guo, Q., You, Q., & Shao-hong, J. (2012) · Journal of Natural Products · doi:10.1021/np300118c · Cited by 38
Escobar, Z., Bjartell, A. S., Canesin, G., Axelsson, S. E., Sterner, O., Hellsten, R., & Johansson, M. H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01814 · Cited by 37
Ficarro, S. B., Browne, C. M., Card, J. D., Alexander, W. M., Zhang, T., Park, E., McNally, R., Dhe-Paganon, S., Seo, H.-S., Lamberto, I., et al. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03394 · Cited by 35
Salas‐Sarduy, E., Landaburu, L. U., Karpiak, J., Madauss, K. P., Cazzulo, J. J., Agüero, F., & Álvarez, V. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-12170-4 · Cited by 37
Borková, L., Hodoň, J., & Urban, M. (2018) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201800163 · Cited by 37
Yen‐Pon, E., Li, B., Acebrón-García-de-Eulate, M., Tomkiewicz, C., Dawson, J. C., Lietha, D., Frame, M. C., Coumoul, X., Garbay, C., Ethève‐Quelquejeu, M., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00250 · Cited by 38
“11 – 12 From a therapeutic point of view, the main advantages of irreversible inhibitors are i) an increase of the target residence time to obtain durable inhibition without maintaining continuous drug exposure; ii) a better ability to avoid drug resistance by reducing the development of resistance…”
Wu, K.-D., Chen, G. S., Liu, J.-R., Hsieh, C.-E., & Chern, J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00270 · Cited by 37
Systematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool
Wen, C., Yan, X., Gu, Q., Du, J., Wu, D., Lu, Y., Zhou, H., & Xu, J. (2019) · Molecules · doi:10.3390/molecules24112183 · Cited by 40
“Nearly 30% of the marketed drugs targeting enzymes are known to act by covalent addition, and targeted covalent inhibitors (TCIs) are becoming important [2].”
BackgroundLibrary Design Strategies To Accelerate Fragment‐Based Drug Discovery
Troelsen, N. S., & Clausen, M. H. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000584 · Cited by 40
Reactive chemistry for covalent probe and therapeutic development
Grams, R. J., & Hsu, K. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.12.002 · Cited by 38
CovBinderInPDB: A Structure-Based Covalent Binder Database
Guo, X.-K., & Zhang, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01216 · Cited by 37
Covalent chemical probes for protein kinases
Serafim, R. A. M., Haarer, L., Pedreira, J. G. B., & Gehringer, M. (2023) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100040 · Cited by 35
Merten, E. M., Sears, J. D., Leisner, T. M., Hardy, P. B., Ghoshal, A., Hossain, M. A., Asressu, K. H., Brown, P. J., Tse, E. G., Stashko, M. A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409166121 · Cited by 43
Small Molecule Inhibitors of Disulfide Bond Formation by the Bacterial DsbA–DsbB Dual Enzyme System
Halili, M. A., Bachu, P., Lindahl, F., Bechara, C., Mohanty, B., Reid, R. C., Scanlon, M. J., Robinson, C. V., Fairlie, D. P., & Martin, J. L. (2015) · ACS Chemical Biology · doi:10.1021/cb500988r · Cited by 49
Deng, H., Wang, C., Su, M., & Ye, F. (2012) · Analytical Chemistry · doi:10.1021/ac301495n · Cited by 37
Awoonor‐Williams, E., & Rowley, C. N. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00897 · Cited by 41
Genetically encoding latent bioreactive amino acids and the development of covalent protein drugs
Wang, N., & Wang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102106 · Cited by 36
Pu, F., Ugrin, S. A., Radosevich, A. J., Chang-Yen, D. A., Sawicki, J. W., Talaty, N. N., Elsen, N. L., & Williams, J. D. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03211 · Cited by 36
Zhang, D., Yan, H.-L., Xu, X., Xu, L., Yin, Z., Chang, S., & Luo, H. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1743282 · Cited by 37
Covalent Inhibitors: Back on track?
Gehringer, M. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0118 · Cited by 41
Profiling the Proteome-Wide Selectivity of Diverse Electrophiles
Zanon, P. R. A., Yu, F., Musacchio, P., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2021) · doi:10.26434/chemrxiv.14186561.v1 · Cited by 35
Covalent Inhibition by a Natural Product-Inspired Latent Electrophile
Byun, D. P., Ritchie, J., Jung, Y., Holewinski, R. J., Kim, H., Tagirasa, R., Ivanic, J., Weekley, C. M., Parker, M. W., Andrésson, Þ., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c00598 · Cited by 37
A simple method for developing lysine targeted covalent protein reagents
Gabizon, R., Tivon, B., Reddi, R. N., van den Oetelaar, M. C. M., Amartely, H., Cossar, P. J., Ottmann, C., & London, N. (2023) · Nature Communications · doi:10.1038/s41467-023-42632-5 · Cited by 38
Ellison, C. M., Enoch, S. J., & Cronin, M. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.629186 · Cited by 35
Targeting Protein Kinases with Selective and Semipromiscuous Covalent Inhibitors
Miller, R. M., & Taunton, J. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-397918-6.00004-5 · Cited by 42
Punthasee, P., Laciak, A. R., Cummings, A. H., Ruddraraju, K. V., Lewis, S. M., Hillebrand, R., Singh, H., Tanner, J. J., & Gates, K. S. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00151 · Cited by 34
Statistical Analysis and Prediction of Covalent Ligand Targeted Cysteine Residues
Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00163 · Cited by 38
Quinone skeleton as a new class of irreversible inhibitors against Staphylococcus aureus sortase A
Hou, X., Wang, M., Wen, Y., Ni, T., Guan, X., Lan, L., Zhang, N., Zhang, A., & Yang, C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.005 · Cited by 35
Design, Synthesis and Characterization of Covalent KDM5 Inhibitors
Vázquez-Rodríguez, S., Wright, M., Rogers, C. M., Cribbs, A. P., Velupillai, S., Philpott, M., Lee, H., Dunford, J. E., Huber, K., Robers, M. B., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201810179 · Cited by 35
Underappreciated Chemical Interactions in Protein–Ligand Complexes
Anighoro, A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_5 · Cited by 35
Correlating Drug–Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability
Davoodi, S., Daryaee, F., Chang, A. T., Walker, S. G., & Tonge, P. J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00484 · Cited by 35
Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics
Yoo, D. Y., Hauser, A. D., Joy, S. T., Bar‐Sagi, D., & Arora, P. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00204 · Cited by 37
Klein, P., Barthels, F., Johé, P., Wagner, A., Tenzer, S., Distler, U., Le, T. A., Schmid, P., Engel, V., Engels, B., et al. (2020) · Molecules · doi:10.3390/molecules25092064 · Cited by 35
Palladium‐Catalyzed Fluorosulfonylvinylation of Organic Iodides
Zha, G., Zheng, Q., Leng, J., Wu, P., Qin, H., & Sharpless, K. B. (2017) · Angewandte Chemie · doi:10.1002/ange.201701162 · Cited by 35
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.